Foghorn Therapeutics ( (FHTX) ) just unveiled an announcement.
On April 28, 2025, Foghorn Therapeutics announced preclinical data for several programs, including their SMARCA2 selective inhibitor FHD-909, at the AACR 2025 Annual Meeting. The company is collaborating with Lilly on the development of FHD-909, which shows potential to improve outcomes for patients with SMARCA4-mutated tumors, particularly in non-small cell lung cancer. This collaboration, initiated in 2021, includes significant financial agreements and aims to address unmet medical needs in cancer treatment.
Spark’s Take on FHTX Stock
According to Spark, TipRanks’ AI Analyst, FHTX is a Underperform.
Foghorn Therapeutics receives a low overall score due to significant financial instability, negative profitability, and technical indicators suggesting bearish momentum. However, promising drug development advancements provide a positive outlook, which slightly mitigates the overall negative assessment.
To see Spark’s full report on FHTX stock, click here.
More about Foghorn Therapeutics
Foghorn Therapeutics Inc. operates in the biotechnology industry, focusing on developing innovative cancer therapies. The company is known for its Gene Traffic Control Platform® and is engaged in advancing first-in-class anticancer agents, with a particular focus on targeting SMARCA2-dependent tumors.
YTD Price Performance: -5.01%
Average Trading Volume: 137,878
Technical Sentiment Signal: Buy
Current Market Cap: $242.5M
For detailed information about FHTX stock, go to TipRanks’ Stock Analysis page.